 - Patients must have had one prior platinum-based chemotherapeutic regimen for management of primary disease containing carboplatin, cisplatin, or another organoplatinum compound; this initial treatment may have included intraperitoneal therapy, consolidation, biologictargeted non-cytotoxic agents e.g., bevacizumab or extended therapy administered after surgical or non-surgical assessment 